We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT05232916
Previous Study | Return to List | Next Study

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects (FLAMINGO-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05232916
Recruitment Status : Recruiting
First Posted : February 10, 2022
Last Update Posted : November 18, 2022
Sponsor:
Information provided by (Responsible Party):
Greenwich LifeSciences, Inc.

Brief Summary:
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third open-label arm will explore GLSI-100 immunotherapy in non-HLA-A*02 positive and HER2/neu positive subjects.

Condition or disease Intervention/treatment Phase
Breast Cancer Biological: Placebo Biological: GLSI-100 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 598 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: HLA-A*02 subjects will be randomized to GLSI-100 or placebo. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third open-label arm will explore GLSI-100 immunotherapy in non-HLA-A*02 positive and HER2/neu positive subjects.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-blind
Primary Purpose: Prevention
Official Title: A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)
Actual Study Start Date : August 11, 2022
Estimated Primary Completion Date : December 2026
Estimated Study Completion Date : December 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: 0.9% Normal Saline
0.9% normal saline in HLA-A*02 positive and HER2/neu positive subjects 0.9% normal saline intradermally every month for first 6 months then every 6 months for next 2.5 years (11 intradermal doses over 3 years)
Biological: Placebo
0.9% Normal Saline

Experimental: GLSI-100
GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects GLSI-100 intradermally (GP2 and GM-CSF syringes), every month for first 6 months then every 6 months for next 2.5 years (11 intradermal doses over 3 years)
Biological: GLSI-100
500 mcg/mL GP2 and 125 mcg/mL GM-CSF

Experimental: GLSI-100, Open-label
Open-label arm: GLSI-100 immunotherapy in non-HLA-A*02 positive and HER2/neu positive subjects GLSI-100 intradermally (GP2 and GM-CSF syringes), every month for first 6 months then every 6 months for next 2.5 years (11 intradermal injections over 3 years)
Biological: GLSI-100
500 mcg/mL GP2 and 125 mcg/mL GM-CSF




Primary Outcome Measures :
  1. Invasive Breast Cancer-free Survival (IBCFS) [ Time Frame: Median 4 years of follow-up (interim analysis planned) ]
    IBCFS is defined as the time from the first dose of study medication until the date of ipsilateral invasive breast cancer recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, or any cause mortality.


Secondary Outcome Measures :
  1. Invasive Disease-free Survival (IDFS) [ Time Frame: Median 4 years of follow-up (interim analysis planned) ]
    IDFS is defined as the time from the first dose of study medication until the date of ipsilateral invasive breast cancer recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, or any cause mortality.

  2. Distant Disease-free Survival (DDFS) [ Time Frame: Median 4 years of follow-up (interim analysis planned) ]
    DDFS will be defined as the time from the first dose of study medication to the time of distant disease recurrence or death.

  3. Overall Survival [ Time Frame: Median 4 years of follow-up (interim analysis planned) ]
    Overall survival will be defined as the time from the first dose of study medication until death from any cause.

  4. Quality of Life Questionnaire Core 30 (QLQ-C30) [ Time Frame: Baseline and 36 months ]
    European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30)

  5. Quality of Life FACT-GP5 [ Time Frame: Baseline and 36 months ]
    FACT-GP5 to assess global side effect impact


Other Outcome Measures:
  1. Immune Response Measurements [ Time Frame: Screening, Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 12, Month 13, Month 18, Month 19, Month 24, Month 25, Month 30, Month 31, Month 36, Month 37, Month 42, Month 48 ]
    Immune response will be measured by Delayed-Type Hypersensitivity (DTH) tests and immunologic assays.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HLA-A*02-positive, unless being enrolled in the third non-HLA-A*02 arm
  • Histologically confirmed diagnosis of HER2/neu positive primary breast cancer
  • Completion of both neoadjuvant and adjuvant trastuzumab-based standard of care breast cancer therapy
  • Stage I, II, or III at presentation with pathologic evidence of residual invasive carcinoma in the breast or axillary lymph nodes (residual disease) at surgery following completion of neoadjuvant therapy -OR- Stage III at presentation with pathologic complete response (pCR) at surgery following completion of neoadjuvant therapy
  • The subject can begin study therapy within 90 days of completion of adjuvant trastuzumab-based therapy and any other standard therapies, but, study therapy can be administered concurrently with endocrine therapy.
  • No clinical evidence of residual or persistent breast cancer per treating physician assessment
  • ECOG 0-2
  • Adequate organ function
  • Negative pregnancy test or evidence of post-menopausal status
  • If of childbearing potential, willing to use a form of highly effective contraception

Exclusion Criteria:

  • Stage IV cancer or metastatic breast cancer at any time
  • Inflammatory breast cancer
  • Receiving other investigational agents
  • Receiving chemotherapy
  • Requiring systemic treatment with corticosteroids or other immunosuppressive therapy
  • History of immunodeficiency or active autoimmune disease
  • A history of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony-stimulating factors such as sargramostim, yeast-derived products, or any component of the investigational product
  • Other malignancies except adequately treated in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin
  • Active infection
  • Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment. Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05232916


Contacts
Layout table for location contacts
Contact: Jaye L Thompson, Ph.D. (832) 819-3232 Jaye.Thompson@GreenwichLifeSciences.com

Locations
Show Show 19 study locations
Sponsors and Collaborators
Greenwich LifeSciences, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Mothaffar F Rimawi, MD Baylor College of Medicine
Layout table for additonal information
Responsible Party: Greenwich LifeSciences, Inc.
ClinicalTrials.gov Identifier: NCT05232916    
Other Study ID Numbers: GLSI-21-01
First Posted: February 10, 2022    Key Record Dates
Last Update Posted: November 18, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Greenwich LifeSciences, Inc.:
HER2/neu positive
Residual disease
pCR
Extended adjuvant
GP2
Immunotherapy
HLA type